Unity Biotechnology Stock Forecast, Price & News

Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions

Is Unity Biotechnology a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Unity Biotechnology stock.
View analyst ratings for Unity Biotechnology or view top-rated stocks.

How has Unity Biotechnology's stock price been impacted by COVID-19 (Coronavirus)?

Unity Biotechnology's stock was trading at $5.39 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, UBX shares have decreased by 61.4% and is now trading at $2.08.
View which stocks have been most impacted by COVID-19.

Are investors shorting Unity Biotechnology?

Unity Biotechnology saw a drop in short interest in the month of October. As of October 15th, there was short interest totaling 1,180,000 shares, a drop of 33.3% from the September 30th total of 1,770,000 shares. Based on an average daily trading volume, of 388,400 shares, the days-to-cover ratio is presently 3.0 days. Currently, 3.4% of the shares of the company are sold short.
View Unity Biotechnology's Short Interest.

When is Unity Biotechnology's next earnings date?

Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Tuesday, March 22nd 2022.
View our earnings forecast for Unity Biotechnology.

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology, Inc. (NASDAQ:UBX) posted its earnings results on Wednesday, November, 10th. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.06.
View Unity Biotechnology's earnings history.

What price target have analysts set for UBX?

3 brokerages have issued twelve-month price targets for Unity Biotechnology's stock. Their forecasts range from $6.00 to $12.00. On average, they expect Unity Biotechnology's share price to reach $8.33 in the next year. This suggests a possible upside of 300.6% from the stock's current price.
View analysts' price targets for Unity Biotechnology or view top-rated stocks among Wall Street analysts.

Who are Unity Biotechnology's key executives?

Unity Biotechnology's management team includes the following people:

• Anirvan Ghosh, Chief Executive Officer & Director
• Nathan Guz, Vice President-Operations
• Lynne Sullivan, Chief Financial Officer
• Jamie Dananberg, Chief Medical Officer
• Susan Lundeen Smuck, Chief Human Resources Officer

Who are some of Unity Biotechnology's key competitors?

Some companies that are related to Unity Biotechnology include Mersana Therapeutics (MRSN), NRx Pharmaceuticals (NRXP), Convey Holding Parent (CNVY), Verastem (VSTM), Zepp Health (ZEPP), Akoya Biosciences (AKYA), Geron (GERN), Spero Therapeutics (SPRO), Beximco Pharmaceuticals (BXP), Invo Bioscience (IVOB), Calliditas Therapeutics AB (publ) (CALT), Rigel Pharmaceuticals (RIGL), BELLUS Health (BLU), Aadi Bioscience (AADI) and Nabriva Therapeutics (NBRV).
View all of UBX's competitors.

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), (CGC), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an initial public offering (IPO) on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

Who are Unity Biotechnology's major shareholders?

Unity Biotechnology's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.63%), Renaissance Technologies LLC (1.16%), Baillie Gifford & Co. (1.07%), Morgan Stanley (0.91%), GSA Capital Partners LLP (0.85%) and Millennium Management LLC (0.80%).
View institutional ownership trends for Unity Biotechnology.

Which institutional investors are selling Unity Biotechnology stock?

UBX stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Morgan Stanley, Millennium Management LLC, Deutsche Bank AG, Russell Investments Group Ltd., Goldman Sachs Group Inc., Dimensional Fund Advisors LP, and Citadel Advisors LLC.
View insider buying and selling activity for Unity Biotechnology or view top insider-selling stocks.

Which institutional investors are buying Unity Biotechnology stock?

UBX stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Renaissance Technologies LLC, Two Sigma Investments LP, Two Sigma Advisers LP, Franklin Resources Inc., Marshall Wace LLP, Moloney Securities Asset Management LLC, and BlackRock Inc..
View insider buying and selling activity for Unity Biotechnology or or view top insider-buying stocks.

How do I buy shares of Unity Biotechnology?

Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $2.08.

How much money does Unity Biotechnology make?

Unity Biotechnology has a market capitalization of $120.07 million.

How many employees does Unity Biotechnology have?

Unity Biotechnology employs 61 workers across the globe.

What is Unity Biotechnology's official website?

The official website for Unity Biotechnology is www.unitybiotechnology.com.

How can I contact Unity Biotechnology?

The company can be reached via phone at (650) 416-1192.